LifeMD Business Summary

LifeMD, Inc. (LFMD) operates as a pure-play, direct-to-patient telehealth and pharmacy company, generating revenue primarily through a recurring subscription-based model and transaction fees for medical consultations and prescription fulfillment. Following the late 2025 divestiture of its WorkSimpli subsidiary, the company has pivoted to a streamlined healthcare focus across three primary verticals: Men’s Health (RexMD), specialized chronic care (ShapiroMD, Cleared), and a rapidly expanding Weight Management program leveraging GLP-1 medications through its virtual primary care platform. The company differentiates itself by integrating a 50-state affiliated provider network with its proprietary 503-A compounding pharmacy capabilities, allowing for personalized medication at scale. LifeMD competes directly with Hims & Hers Health, Ro (Roman), and Thirty Madison, positioning itself as a high-growth, vertically integrated alternative that bridges the gap between digital-first wellness and traditional primary care through insurance-enabled services and strategic partnerships with pharmaceutical leaders like Novo Nordisk. The leadership team is led by Chairman and CEO Justin Schreiber, a co-founder and experienced venture investor (JLS Ventures) who has steered the company’s transition from a marketing-centric entity to a clinical healthcare provider. He is supported by co-founder Stefan Galluppi, who serves as Chief Innovation Officer and was instrumental in building the company’s direct-to-consumer technology infrastructure. The executive suite includes Chief Technology Officer Dennis Wijnker, who oversees the platform’s EMR and algorithmic scheduling systems, and CFO Marc Benathen, formerly of Blink Fitness and ANN, Inc. The company’s board of directors features prominent medical and financial figures, including Dr. Calum MacRae of Harvard Medical School and Dr. Anthony Puopolo. Notable institutional backing is provided by major asset managers including BlackRock, Vanguard, and State Street, alongside strategic investment from ApolloMed, reflecting a robust institutional interest in LifeMD’s scalable virtual care model.